PRFX - PRF Technologies Ltd.

2.62
-0.130   -4.962%

Share volume: 29,259
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.26%

PREVIOUS CLOSE
CHG
CHG%
$2.75
-0.13
-0.05%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
0%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 0%
Performance
5 Days
-10.58%
1 Month
-12.08%
3 Months
174.86%
6 Months
88.49%
1 Year
-14.38%
2 Year
25.36%
Key data
Stock price
$2.62
P/E Ratio 
0.00
DAY RANGE
$2.53 - $2.76
EPS 
N/A
52 WEEK RANGE
$0.58 - $3.71
52 WEEK CHANGE
-$11.78
MARKET CAP 
1.567 M
YIELD 
N/A
SHARES OUTSTANDING 
7.026 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-14-2025
BETA 
0.14
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$28,819
AVERAGE 30 VOLUME 
$644,690
Company detail
CEO: Ilan Hadar
Region: US
Website: painreform.com
Employees: 4
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

PainReform Ltd. engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair.

Recent news